Related Experiment Video
Updated: Jul 7, 2026

Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones
Published on: November 30, 2016
Plasmidic CpG sequences induce tumor microenvironment modifications in a rat liver metastasis model
Samuel Bertin1, Fabienne Anjuere, Adolfo Gavelli
1INSERM Unité 638, Université de Nice Sophia Antipolis, Faculté de Médecine, Avenue de Valombrose, F-06107 Nice Cédex 2, France.
Abstract:
Bacterial DNA contains unmethylated cytosine-phosphate-guanine (CpG) motifs which are recognized by mammalian immune cells as a danger signal indicating an infection. These immunostimulatory properties led to the use of oligodeoxynucleotides bearing CpG motifs (CpG-ODN) for cancer treatment in preclinical and clinical studies. Although naked DNA administration presently represents 18% of the gene therapy clinical trials worldwide, most of the work regarding the effects of unmethylated CpG sequences was performed using CpG-ODN. In the present study, we analyzed early induced tumor microenvironment modifications in a rat liver metastasis model after intratumoral injection of a plasmid used in suicide gene therapy. We first showed that plasmidic CpG motifs were active, i.e. able to induce IFN-gamma secretion by rat splenocytes. Then, we compared tumor-infiltrating immune cells 24 h after injection of native or SssI-treated plasmid, in which immunostimulatory CpG motifs have been inactivated by methylation. The presence of active plasmidic CpG sequences within the tumor was associated with a decrease in the number of tumor-infiltrating conventional dendritic cells and an upregulation of the CCR7 chemokine receptor responsible for lymph node homing. We also observed an increase in plasmacytoid dendritic cells and natural killer cell infiltration within the tumors as well as an increased mRNA expression of three cytokines/chemokines (IL-1beta, IL-10 and IL-18). These data suggest that, although suicide plasmid injection without prodrug treatment is not sufficient to observe a therapeutic effect, the presence of plasmidic CpG motifs within the tumor induces the recruitment and activation of the immune cells involved in antitumor response. These early cellular and molecular events should facilitate the induction of the immune response against tumor antigens released after in situ drug production.
Insights
Bacterial DNA
Area of Science:
- Immunology
- Molecular Biology
- Oncology
Background:
- Bacterial DNA's unmethylated cytosine-phosphate-guanine (CpG) motifs trigger immune responses.
- CpG motifs are used in cancer treatment via CpG oligodeoxynucleotides (CpG-ODN).
- Naked DNA in gene therapy trials is increasing, yet CpG effects are mainly studied with CpG-ODN.
Purpose of the Study:
- To analyze early tumor microenvironment changes after intratumoral plasmid injection in a rat liver metastasis model.
- To investigate the role of plasmidic CpG motifs in immune cell recruitment and activation.
Main Methods:
- Intratumoral injection of native or SssI-treated plasmid (CpG motifs inactivated by methylation) in a rat liver metastasis model.
- Analysis of plasmidic CpG motif activity by measuring IFN-gamma secretion from rat splenocytes.
- Flow cytometry and mRNA expression analysis of tumor-infiltrating immune cells and cytokines/chemokines 24 hours post-injection.
Main Results:
- Plasmidic CpG motifs were confirmed to be immunostimulatory, inducing IFN-gamma secretion.
- Active plasmidic CpG sequences decreased conventional dendritic cell numbers but increased plasmacytoid dendritic cells and natural killer cells.
- Upregulation of CCR7 and increased expression of IL-1beta, IL-10, and IL-18 were observed in tumors with active CpG motifs.
Conclusions:
- Active plasmidic CpG motifs in tumors recruit and activate immune cells crucial for antitumor responses.
- These early immune events, driven by plasmidic CpG, can enhance immune responses against tumor antigens.
- While not sufficient for therapeutic effect alone, CpG-driven immune modulation shows potential in cancer gene therapy.

